These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 23312606)

  • 1. Vancomycin pharmacodynamics and survival in patients with methicillin-resistant Staphylococcus aureus-associated septic shock.
    Zelenitsky S; Rubinstein E; Ariano R; Iacovides H; Dodek P; Mirzanejad Y; Kumar A;
    Int J Antimicrob Agents; 2013 Mar; 41(3):255-60. PubMed ID: 23312606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High vancomycin minimum inhibitory concentration is a predictor of mortality in meticillin-resistant Staphylococcus aureus bacteraemia.
    Wi YM; Kim JM; Joo EJ; Ha YE; Kang CI; Ko KS; Chung DR; Song JH; Peck KR
    Int J Antimicrob Agents; 2012 Aug; 40(2):108-13. PubMed ID: 22633565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methicillin-resistant Staphylococcus aureus bacteremia in hemodialysis and nondialysis patients.
    Kan LP; Lin JC; Chiu SK; Yeh YC; Lin TY; Yang YS; Wang YC; Wang NC; Yeh KM; Chang FY
    J Microbiol Immunol Infect; 2014 Feb; 47(1):15-22. PubMed ID: 23040238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The change and significance of vancomycin minimal inhibitory concentration against methicillin-resistant Staphylococcus aureus isolates from inpatients with lower respiratory tract infection].
    Yang W; He B; Ning YZ; Li Y
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Apr; 36(4):288-92. PubMed ID: 23945344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia.
    Jung Y; Song KH; Cho Je; Kim HS; Kim NH; Kim TS; Choe PG; Chung JY; Park WB; Bang JH; Kim ES; Park KU; Park SW; Kim HB; Kim NJ; Oh MD
    Int J Antimicrob Agents; 2014 Feb; 43(2):179-83. PubMed ID: 24315788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A stewardship program's retrospective evaluation of vancomycin AUC24/MIC and time to microbiological clearance in patients with methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis.
    Gawronski KM; Goff DA; Brown J; Khadem TM; Bauer KA
    Clin Ther; 2013 Jun; 35(6):772-9. PubMed ID: 23795575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.
    Hidayat LK; Hsu DI; Quist R; Shriner KA; Wong-Beringer A
    Arch Intern Med; 2006 Oct; 166(19):2138-44. PubMed ID: 17060545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vancomycin: we can't get there from here.
    Patel N; Pai MP; Rodvold KA; Lomaestro B; Drusano GL; Lodise TP
    Clin Infect Dis; 2011 Apr; 52(8):969-74. PubMed ID: 21460308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of teicoplanin MICs on treatment outcomes among patients with teicoplanin-treated methicillin-resistant Staphylococcus aureus bacteraemia: a hospital-based retrospective study.
    Chang HJ; Hsu PC; Yang CC; Siu LK; Kuo AJ; Chia JH; Wu TL; Huang CT; Lee MH
    J Antimicrob Chemother; 2012 Mar; 67(3):736-41. PubMed ID: 22169187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of methicillin-resistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2 μg/mL to vancomycin: old (trimethoprim/sulfamethoxazole) versus new (daptomycin or linezolid) agents.
    Campbell ML; Marchaim D; Pogue JM; Sunkara B; Bheemreddy S; Bathina P; Pulluru H; Chugh N; Wilson MN; Moshos J; Ku K; Hayakawa K; Martin ET; Lephart PR; Rybak MJ; Kaye KS
    Ann Pharmacother; 2012 Dec; 46(12):1587-97. PubMed ID: 23212935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of pharmacodynamic target attainment with vancomycin treatment of bacteremia due to Staphylococcus aureus methicillin resistant].
    Lepe JA; Gil-Navarro MV; Santos-Rubio MD; Bautista J; Aznar J
    Rev Esp Quimioter; 2010 Mar; 23(1):43-7. PubMed ID: 20232023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough?
    Lodise TP; Drusano GL; Zasowski E; Dihmess A; Lazariu V; Cosler L; McNutt LA
    Clin Infect Dis; 2014 Sep; 59(5):666-75. PubMed ID: 24867791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes and costs associated with a history of vancomycin exposure in patients with MRSA-related complicated bacteremia and infective endocarditis.
    Brown J; Brown KA; Forrest A
    Clin Ther; 2011 Oct; 33(10):1475-82. PubMed ID: 21925733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vancomycin MICs do not predict the outcome of methicillin-resistant Staphylococcus aureus bloodstream infections in correctly treated patients.
    Rojas L; Bunsow E; Muñoz P; Cercenado E; Rodríguez-Créixems M; Bouza E
    J Antimicrob Chemother; 2012 Jul; 67(7):1760-8. PubMed ID: 22556382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
    Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of Vancomycin plus a β-Lactam versus Vancomycin Only for Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia.
    Truong J; Veillette JJ; Forland SC
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationships between vancomycin minimum inhibitory concentration, dosing strategies, and outcomes in methicillin-resistant Staphylococcus aureus bacteremia.
    Clemens EC; Chan JD; Lynch JB; Dellit TH
    Diagn Microbiol Infect Dis; 2011 Dec; 71(4):408-14. PubMed ID: 21924852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial dosage regimen of vancomycin for septic shock patients: a pharmacokinetic study and Monte Carlo simulation.
    Katip Bpharm W; Jaruratanasirikul S; Pattharachayakul S; Wongpoowarak W; Jitsurong A
    J Med Assoc Thai; 2014 Nov; 97(11):1209-19. PubMed ID: 25675687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia.
    Walraven CJ; North MS; Marr-Lyon L; Deming P; Sakoulas G; Mercier RC
    J Antimicrob Chemother; 2011 Oct; 66(10):2386-92. PubMed ID: 21775337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study.
    Moore CL; Osaki-Kiyan P; Haque NZ; Perri MB; Donabedian S; Zervos MJ
    Clin Infect Dis; 2012 Jan; 54(1):51-8. PubMed ID: 22109947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.